Fernandez J, De Boissieu P, Galbraith M (2025) Health technology assessment in Europe: A comparison of organizations and introduction to the European regulation. Presse Médicale 54:104282. https://doi.org/10.1016/j.lpm.2025.104282

Article  PubMed  Google Scholar 

NICE (2025) About technology appraisal guidance. https://www.nice.org.uk/what-nice-does/our-guidance/about-technology-appraisal-guidance. Accessed 3 Feb 2026

Allen N, Liberti L, Walker SR, Salek S (2017) A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment? Front Pharmacol 8:384. https://doi.org/10.3389/fphar.2017.00384

Article  PubMed  PubMed Central  Google Scholar 

Sarri G, Vinals L, Leisle L et al (2025) Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges. J Comp Eff Res 14:e240240. https://doi.org/10.57264/cer-2024-0240

Article  PubMed  PubMed Central  Google Scholar 

Epstein D, Espín J (2020) Evaluation of new medicines in Spain and comparison with other European countries. Gac Sanit 34:133–140. https://doi.org/10.1016/j.gaceta.2019.02.009

Article  PubMed  Google Scholar 

Serrano-Aguilar P, Asua-Batarrita J, Molina-López MT et al (2019) The Spanish Network of Agencies for Health Technology Assessment and Services of the National Health System (RedETS). Int J Technol Assess Health Care 35:176–180. https://doi.org/10.1017/S0266462319000205

Article  PubMed  Google Scholar 

Garau M, Jommi C (2023) Around The World in HTAs. Italy – What’s Next?

Urbina I, Adams R, Fernandez J et al (2024) Advancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTA. Int J Technol Assess Health Care 40:e75. https://doi.org/10.1017/S0266462324004689

Article  PubMed  PubMed Central  Google Scholar 

Regulation (EU) 2021/2282 of the European parliament and of the council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. Directorate-General for Health and Food Safety, 15 December 2021. https://health.ec.europa.eu/publications/regulation-eu-20212282-health-technology-assessment_en. Accessed 19 June 2026.

Guidance on the scoping process, Directorate-General for Health and Food Safety (2024). https://health.ec.europa.eu/document/download/7be11d76-9a78-426c-8e32-79d30a115a64_en?filename=hta_jca_scoping-process_en.pdf. Accessed 19 June 2026

European Commission. Updated - List of ongoing joint clinical assessments. Directorate-General for Health and Food Safety (2025). https://health.ec.europa.eu/latest-updates/updated-list-ongoing-joint-clinical-assessments-2025-09-02_en. Accessed 27 May 2026

A significant step in the new EU HTA process: first assessment completed (2016). https://www.iqwig.de/en/presse/press-releases/press-releases-detailpage_176320.html.  Accessed 19 June 2026

Zhang N, Wu J, Wang Q et al (2023) Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J 13:82. https://doi.org/10.1038/s41408-023-00853-3

Article  PubMed  PubMed Central  Google Scholar 

Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. Directorate-General for Health and Food Safety (2024). https://health.ec.europa.eu/latest-updates/methodological-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons-2024-03-25_en. Accessed 27 May 2026

Basu A, Thomas SK, Chapman RH, Spangler J (2025) HTA Evidence in Rare Diseases: Just Rare or Also Special? PharmacoEconomics 43:1271–1279. https://doi.org/10.1007/s40273-025-01538-4

Article  PubMed  PubMed Central  Google Scholar 

Trapani D, Tay-Teo K, Tesch ME et al (2022) Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Curr Oncol 29:5774–5791. https://doi.org/10.3390/curroncol29080455

Article  PubMed  PubMed Central  Google Scholar 

(2026) Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons

Practical Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. Directorate-General for Health and Food Safety (2024). https://health.ec.europa.eu/latest-updates/practical-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons-2024-03-25_en. Accessed 27 May 2026

Van Beekhuizen S, Che M, Monfort L et al (2025) Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments. PharmacoEconomics - Open 9:597–609. https://doi.org/10.1007/s41669-025-00575-1

Article  PubMed  PubMed Central  Google Scholar 

Skipka G, Wieseler B, Kaiser T et al (2016) Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. Biom J 58:43–58. https://doi.org/10.1002/bimj.201300274

Article  PubMed  Google Scholar 

Committee for Medicinal Products for Human Use (CHMP) https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp. Accessed 3 Feb 2026

Haute Autorité de Santé Les Médicaments. https://www.has-sante.fr/jcms/fc_2875171/fr/resultat-de-recherche?text=&tmpParam=typesf%3Dtechnologies%2Fgenerated.Medicament&typesf=technologies%2Fgenerated.Medicament&opSearch. Accessed 3 Feb 2026

IQWiG, Project and results. https://www.iqwig.de/en/projects/projects-results/#searchQuery=query=*&page=1&rows=10&sortBy=score&sortOrder=desc&facet.filter.language=en. Accessed 3 Feb 2026

National Centre for Pharmacoeconomics Ireland. Drugs. https://www.ncpe.ie/category/drugs/. Accessed 3 Feb 2026

Tandvårds- och läkemedelsförmånsverket Hälsoekonomiska bedömningar och rapporter klinikläkemedel. https://www.tlv.se/lakemedelsforetag/halsoekonomiska-bedomningar-och-rapporter-kliniklakemedel.html. Accessed 3 Feb 2026

Zorginstituut Nederland Working methods and procedures. https://english.zorginstituutnederland.nl/documents. Accessed 3 Feb 2026

National Institue for Health and Care Excellence Published: Guidance, quality standards and advice. https://www.nice.org.uk/guidance/published?sp=on. Accessed 3 Feb 2026

Scottish Medicines Consortium. Medicines advice. https://scottishmedicines.org.uk/medicines-advice/. Accessed 3 Feb 2026

Talvey EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/talvey. Accessed 3 Feb 2026

Lynozyfic EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/lynozyfic. Accessed 3 Feb 2026

Elrexfio EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio. Accessed 3 Feb 2026

Tepkinly EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly. Accessed 3 Feb 2026

Ordspono EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/ordspono. Accessed 3 Feb 2026

Inaqovi EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/inaqovi. Accessed 3 Feb 2026

Enrylaze EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze. Accessed 3 Feb 2026

Omjjara EPAR - Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara. Accessed 3 Feb 2026

European medicine agency. Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp. Accessed 3 Feb 2026. 

TEPKINLY (epcoritamab) - Diff use large B-cell lymphoma (DLBCL). https://www.has-sante.fr/upload/docs/evamed/CT-20582_TEPKINLY_PIC_INS_AvisDef_CT20582.pdf. Accessed 3 Feb 2026

Epcoritamab (diff uses großzelliges B-Zell-Lymphom [DLBCL]) Nutzenbewertung gemäß § 35a SGB V. https://www.iqwig.de/download/a24-108_epcoritamab_nutzenbewertung-35a-sgb-v_v1-0.pdf. Accessed 3 Feb 2026

Epcoritamab for treating relapsed or refractory diff use large B-cell lymphoma after 2 or more systemic treatments. https://www.nice.org.uk/guidance/ta954/resources/epcoritamab-for-treating-relapsed-or-refractory-diffuse-large-bcell-lymphoma-after-2-or-more-systemic-treatments-pdf-82615729002181. Accessed 3 Feb 2026. 

Epcoritamab concentrate for solution for injection and solution for injection (Tepkinly®). https://scottishmedicines.org.uk/media/8387/epcoritamab-tepkinly-final-may-2024-amended-050624-for-website.pdf. Accessed 3 Feb 2026

Hälsoekonomisk bedömning Klinikläkemedelsuppdraget Tepkinly (epkoritamab). https://www.tlv.se/download/18.6e6dd587192b793d8b812365/1729849560071/bed241025_tepkinly_3760-2023.pdf. Accessed 3 Feb 2026

Advies - niet vergoeden epcoritamab (Tepkinly®) voor de behandeling van lymfeklierkanker. https://www.zorginstituutnederland.nl/documenten/2025/05/27/pakketadvies-epcoritamab-tepkinly-voor-de-behandeling-van-lymfeklierkanker. Accessed 3 Feb 2026

Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:1800–1808. https://doi.org/10.1182/blood-2017-03-769620

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL et al (2021) Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv 5:4149–4155. https://doi.org/10.1182/bloodadvances.2020003848

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38:155–165. https://doi.org/10.1200/JCO.19.00172

Article  CAS  PubMed  Google Scholar 

Sehn LH, Hertzberg M, Opat S et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6:533–543. https://doi.org/10.1182/bloodadvances.2021005794

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ip A, Rosenthal A, Mutebi A et al (2023) Comparison of clinical outcomes in patients with relapsed/refractory large B-cell lymphoma treated with epcoritamab versus chemoimmunotherapy. Hematol Oncol 41:433–434. https://doi.org/10.1002/hon.3164_319

Article  Google Scholar 

Schuster SJ, Tam CS, Borchmann P et al (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22:1403–1415. https://doi.org/10.1016/S1470-2045(21)00375-2

Article  CAS  PubMed  Google Scholar 

TALVEY (talquetamab) - Multiple myeloma. https://www.has-sante.fr/upload/docs/evamed/CT-20821_TALVEY_PIC_INS_AvisDef_CT20821.pdf. Accessed 3 Feb 2026

NCPE Assessment Technical Summary Talquetamab (Talvey®) HTA ID 23057. https://www.ncpe.ie/wp-content/uploads/2025/04/Talquetamab-Technical-Summary-23057.pdf. Accessed 3 Feb 2026

Hälsoekonomisk bedömning Klinikläkemedel Talvey (talkvetamab). https://www.tlv.se/download/18.10591cca19271671be2317b7/1729059208756/bed241015_talvey_3309-2023.pdf. Accessed 3 Feb 2026

Talquetamab solution for injection (Talvey®). https://scottishmedicines.org.uk/media/8521/talquetamab-talvey-non-sub-final-july-2024-for-website.pdf. Accessed 3 Feb 2026

Rücker FG, Du L, Luck TJ et al (2022) Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia 36:90–99. https://doi.org/10.1038/s41375-021-01323-0

Article